MedDataX Logo

Prevention of Seasonal Affective Disorder

NCT ID: NCT00046241

Last Updated: 2017-01-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

300 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-09-30

Study Completion Date

2003-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a placebo controlled study evaluating the effectiveness of medication in preventing depressive episodes in subjects with a history of Seasonal Affective Disorder (SAD).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Seasonal Affective Depression (SAD) Study

NCT00069459

Depressive Disorder
COMPLETED PHASE1

Prevention of Seasonal Affective Disorder

NCT00046449

Seasonal Affective Disorder (SAD)
COMPLETED PHASE3

Wellbutrin XL for Dysthymic Disorder

NCT00225251

Dysthymic Disorder
COMPLETED PHASE4

Effects of Bupropion in Depression

NCT02104128

Depression
COMPLETED NA

Bupropion Hydrochloride 300 mg Extended Release Tablets Under Fasting Conditions

NCT01046214

Depressive Disorder
TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Seasonal Affective Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Extended-release bupropion hydrochloride

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient has a history of Major Depressive Disorder (MDD) with a seasonal pattern.

Exclusion Criteria

* Patient has a current or past history of seizure disorder or brain injury.
* Patient has a history or current diagnosis of anorexia nervosa or bulimia.
* Patient has recurrent summer depression more frequently than winter depression.
* Patient has primary diagnosis of panic disorder, Obsessive Compulsive Disorder (OCD), Posttraumatic Stress Disorder (PTSD), acute distress disorder, bipolar II disorder or other psychotic disorders.
* Patient has initiated psychotherapy within the last 3 months.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

GlaxoSmithKline

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

GSK Clinical Trial, MD

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

GSK Clinical Trials Call Center

Anchorage, Alaska, United States

Site Status

GSK Clinical Trials Call Center

Hamden, Connecticut, United States

Site Status

GSK Clinical Trials Call Center

Boise, Idaho, United States

Site Status

GSK Clinical Trials Call Center

Chicago, Illinois, United States

Site Status

GSK Clinical Trials Call Center

Edwardsville, Illinois, United States

Site Status

GSK Clinical Trials Call Center

Oak Brook, Illinois, United States

Site Status

GSK Clinical Trials Call Center

Oakbrook Terrace, Illinois, United States

Site Status

GSK Clinical Trials Call Center

Lafayette, Indiana, United States

Site Status

GSK Clinical Trials Call Center

Cedar Rapids, Iowa, United States

Site Status

GSK Clinical Trials Call Center

Overland Park, Kansas, United States

Site Status

GSK Clinical Trials Call Center

Baltimore, Maryland, United States

Site Status

GSK Clinical Trials Call Center

Rockville, Maryland, United States

Site Status

GSK Clinical Trials Call Center

Belmont, Massachusetts, United States

Site Status

GSK Clinical Trials Call Center

Detroit, Michigan, United States

Site Status

GSK Clinical Trials Call Center

Farmington Hills, Michigan, United States

Site Status

GSK Clinical Trials Call Center

Minneapolis, Minnesota, United States

Site Status

GSK Clinical Trials Call Center

St Louis, Missouri, United States

Site Status

GSK Clinical Trials Call Center

Omaha, Nebraska, United States

Site Status

GSK Clinical Trials Call Center

Clementon, New Jersey, United States

Site Status

GSK Clinical Trials Call Center

Kenilworth, New Jersey, United States

Site Status

GSK Clinical Trials Call Center

Princeton, New Jersey, United States

Site Status

GSK Clinical Trials Call Center

Albany, New York, United States

Site Status

GSK Clinical Trials Call Center

New York, New York, United States

Site Status

GSK Clinical Trials Call Center

New York, New York, United States

Site Status

GSK Clinical Trials Call Center

New York, New York, United States

Site Status

GSK Clinical Trials Call Center

Rochester, New York, United States

Site Status

GSK Clinical Trials Call Center

Beachwood, Ohio, United States

Site Status

GSK Clinical Trials Call Center

Cincinnati, Ohio, United States

Site Status

GSK Clinical Trials Call Center

Dayton, Ohio, United States

Site Status

GSK Clinical Trials Call Center

Marion, Ohio, United States

Site Status

GSK Clinical Trials Call Center

Eugene, Oregon, United States

Site Status

GSK Clinical Trials Call Center

Portland, Oregon, United States

Site Status

GSK Clinical Trials Call Center

Portland, Oregon, United States

Site Status

GSK Clinical Trials Call Center

Havertown, Pennsylvania, United States

Site Status

GSK Clinical Trials Call Center

Jenkintown, Pennsylvania, United States

Site Status

GSK Clinical Trials Call Center

Philadelphia, Pennsylvania, United States

Site Status

GSK Clinical Trials Call Center

East Providence, Rhode Island, United States

Site Status

GSK Clinical Trials Call Center

Woodstock, Vermont, United States

Site Status

GSK Clinical Trials Call Center

Falls Church, Virginia, United States

Site Status

GSK Clinical Trials Call Center

Bellevue, Washington, United States

Site Status

GSK Clinical Trials Call Center

Seattle, Washington, United States

Site Status

GSK Clinical Trials Call Center

Spokane, Washington, United States

Site Status

GSK Clinical Trials Call Center

Brown Deer, Wisconsin, United States

Site Status

GSK Clinical Trials Call Center

Calgary, Alberta, Canada

Site Status

GSK Clinical Trials Call Center

Edmonton, Alberta, Canada

Site Status

GSK Clinical Trials Call Center

Kelowna, British Columbia, Canada

Site Status

GSK Clinical Trials Call Center

Winnipeg, Manitoba, Canada

Site Status

GSK Clinical Trials Call Center

Toronto, Ontario, Canada

Site Status

GSK Clinical Trials Call Center

Toronto, Ontario, Canada

Site Status

GSK Clinical Trials Call Center

Montreal, Quebec, Canada

Site Status

GSK Clinical Trials Call Center

Sherbrooke, Quebec, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AK130930

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder
NCT02129751 NOT_YET_RECRUITING PHASE4
To Demonstrate the Relative Bioavailability of Bupropion HCI 100 mg Tablets Under Fasting Conditions
NCT00883155 COMPLETED PHASE1
To Demonstrate the Relative Bioavailability of Bupropion HCI 300 mg Extended-Release Tablets Under Fasting Conditions
NCT00861939 COMPLETED PHASE1
Bupropion Stereoselective Disposition and CYP2D6-mediated Drug Interactions in Healthy Volunteers
NCT03420469 COMPLETED EARLY_PHASE1
A Study to Evaluate Pharmacokinetics, Safety and Tolerability of Extended-release Bupropion Hydrochloride Tablets in Chinese Healthy Volunteers
NCT02698553 COMPLETED PHASE1
Sexual Functioning Study With Antidepressants
NCT00316160 COMPLETED PHASE4
Clinical Study of Generic and Brand Bupropion in Depression
NCT02209597 COMPLETED PHASE4
Wellbutrin XL, Major Depressive Disorder and Breast Cancer
NCT00234195 COMPLETED PHASE4
A Trial of Dextromethorphan and Bupropion Sustained-Release Tablets in Patients With Major Depressive Disorder
NCT06958692 RECRUITING PHASE3
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
NCT06223880 RECRUITING PHASE4
Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs Placebo
NCT04221230 COMPLETED PHASE2
Assessing Symptomatic Clinical Episodes in Depression
NCT03595579 COMPLETED PHASE2
A Study of Fluoxetine in Major Depressive Disorder (MDD) Short-Term Dosing
NCT01808612 COMPLETED PHASE3
Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
NCT06029426 COMPLETED PHASE3
A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine
NCT06280235 COMPLETED PHASE2
An 8 Week Study Of Adults Diagnosed With Major Depressive Disorder
NCT00057226 COMPLETED PHASE2
Interventional Study of Wellbutrin XL in Major Depressive Disorder With Atypical Features
NCT01477931 COMPLETED PHASE4
A Study Evaluating Duloxetine in Patients Hospitalized for Severe Depression
NCT00422162 COMPLETED PHASE4
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
NCT00057213 COMPLETED PHASE2
Safety and Pharmacology Study of BMS-866949
NCT01124344 TERMINATED PHASE1
Open-Label Treatment With Duloxetine Hydrochloride Once-Daily Dosing for Evaluation of Stabilization Dose in Patients With Major Depression
NCT00042562 COMPLETED PHASE3
MDD POC Study GSK372475 Subjects Depressive Disease
NCT00420641 COMPLETED PHASE2
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
NCT01309945 COMPLETED PHASE2
A Study Comparing Duloxetine and Placebo in Assessing Energy and Vitality in Major Depressive Disorder (MDD) Patients
NCT00536471 COMPLETED PHASE4
Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment
NCT02400346 COMPLETED PHASE3